Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-5-6
pubmed:abstractText
Frontotemporal lobar degeneration (FTLD) is a clinically, genetically and pathologically heterogeneous disorder. Within FTLD with ubiquitin-positive inclusions (FTLD-U), a new pathological subtype named FTLD-FUS was recently found with fused in sarcoma (FUS) positive, TDP-43-negative inclusions, and striking atrophy of the caudate nucleus. The aim of this study was to determine the frequency of FTLD-FUS in our pathological FTLD series, and to describe the clinical, neuroimaging and neuropathological features of FTLD-FUS, especially caudate atrophy. Demographic and clinical data collected prospectively from 387 patients with frontotemporal dementia (FTD) yielded 74 brain specimens. Immunostaining was carried out using a panel of antibodies, including AT-8, ubiquitin, p62, FUS, and TDP-43. Cortical and caudate atrophy on MRI (n = 136) was rated as normal, mild-moderate or severe. Of the 37 FTLD-U cases, 33 were reclassified as FTLD-TDP and four (0.11, 95%: 0.00-0.21) as FTLD-FUS, with ubiquitin and FUS-positive, p62 and TDP-43-negative neuronal intranuclear inclusions (NII). All four FTLD-FUS cases had a negative family history, behavioural variant FTD (bvFTD), and three had an age at onset <or=40 years. MRI revealed mild-moderate or severe caudate atrophy in all, with a mean duration from onset till MRI of 63 months (range 16-119 months). In our total clinical FTD cohort, we found 11 patients (0.03; 95% CI: 0.01-0.05) with bvFTD, negative family history, and age at onset <or=40 years. Caudate atrophy was present in 10 out of 136 MRIs, and included all four FUS-cases. The newly identified FTLD-FUS has a frequency of 11% in FTLD-U, and an estimated frequency of three percent in our clinical FTD cohort. The existence of this pathological subtype can be predicted with reasonable certainty by age at onset <or=40 years, negative family history, bvFTD and caudate atrophy on MRI.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-12654969, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-15505152, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-17003490, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-17023659, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-17228326, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-17360763, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-17458552, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-17469116, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-17917582, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18080129, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18204254, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18346206, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18362096, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18379439, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18379440, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18536926, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18553091, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18703462, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18771956, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-18782907, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-19251627, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-19251628, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-8232972, http://linkedlifedata.com/resource/pubmed/commentcorrection/19946779-9856190
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1432-1459
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
257
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
747-53
pubmed:dateRevised
2010-9-28
pubmed:meshHeading
pubmed-meshheading:19946779-Adult, pubmed-meshheading:19946779-Age of Onset, pubmed-meshheading:19946779-Brain, pubmed-meshheading:19946779-Caudate Nucleus, pubmed-meshheading:19946779-Cerebral Cortex, pubmed-meshheading:19946779-DNA-Binding Proteins, pubmed-meshheading:19946779-Female, pubmed-meshheading:19946779-Frontotemporal Lobar Degeneration, pubmed-meshheading:19946779-Humans, pubmed-meshheading:19946779-Immunohistochemistry, pubmed-meshheading:19946779-Magnetic Resonance Imaging, pubmed-meshheading:19946779-Male, pubmed-meshheading:19946779-Middle Aged, pubmed-meshheading:19946779-Prospective Studies, pubmed-meshheading:19946779-RNA-Binding Protein FUS, pubmed-meshheading:19946779-Severity of Illness Index, pubmed-meshheading:19946779-Time Factors, pubmed-meshheading:19946779-Ubiquitin
pubmed:year
2010
pubmed:articleTitle
Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
pubmed:affiliation
Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Room Hs 611, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't